S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
A gold storm is coming… (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
A gold storm is coming… (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
A gold storm is coming… (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
A gold storm is coming… (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
A gold storm is coming… (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
A gold storm is coming… (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
A gold storm is coming… (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
A gold storm is coming… (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
A gold storm is coming… (Ad)
Disney World unions vote down offer covering 45,000 workers
Route to Super Bowl dangerous for Mexico's avocado haulers
NASDAQ:GLYC

GlycoMimetics - GLYC Stock Forecast, Price & News

$3.09
+0.06 (+1.98%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.97
$3.12
50-Day Range
$2.04
$3.39
52-Week Range
$0.51
$3.60
Volume
380,625 shs
Average Volume
986,260 shs
Market Capitalization
$161.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

GlycoMimetics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.56% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$2.85 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.91) to ($0.65) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

608th out of 1,028 stocks

Pharmaceutical Preparations Industry

294th out of 501 stocks

GLYC stock logo

About GlycoMimetics (NASDAQ:GLYC) Stock

GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.

Receive GLYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter.

GLYC Stock News Headlines

Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
This Small Pharma Company Could Develop Into a Nice Trade
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
GlycoMimetics (GLYC) Upgraded to Buy: Here's Why
See More Headlines
Receive GLYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter.

GLYC Company Calendar

Last Earnings
11/09/2022
Today
2/04/2023
Next Earnings (Estimated)
3/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GLYC
Employees
52
Year Founded
N/A

Profitability

Net Income
$-63,430,000.00
Pretax Margin
-57,921.50%

Debt

Sales & Book Value

Annual Sales
$92,625.00
Book Value
$1.58 per share

Miscellaneous

Free Float
48,230,000
Market Cap
$161.99 million
Optionable
Optionable
Beta
2.08

Key Executives

  • Harout Semerjian
    President, Chief Executive Officer & Director
  • Brian M. Hahn
    Chief Financial Officer & Senior VP-Finance
  • John L. Magnani
    Chief Scientific Officer & Senior VP-Research
  • Deepak Tiwari
    Vice President-Technical Operations
  • Edwin P. Rock
    Chief Medical Officer & Senior Vice President













GLYC Stock - Frequently Asked Questions

Should I buy or sell GlycoMimetics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GLYC shares.
View GLYC analyst ratings
or view top-rated stocks.

How have GLYC shares performed in 2023?

GlycoMimetics' stock was trading at $3.03 at the beginning of 2023. Since then, GLYC stock has increased by 2.0% and is now trading at $3.09.
View the best growth stocks for 2023 here
.

When is GlycoMimetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our GLYC earnings forecast
.

How were GlycoMimetics' earnings last quarter?

GlycoMimetics, Inc. (NASDAQ:GLYC) announced its quarterly earnings results on Wednesday, November, 9th. The biotechnology company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.10.

What other stocks do shareholders of GlycoMimetics own?
What is GlycoMimetics' stock symbol?

GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."

Who are GlycoMimetics' major shareholders?

GlycoMimetics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Intellectus Partners LLC (0.16%), AE Wealth Management LLC (0.05%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Brian M Hahn, Bvf Partners L P/Il, Daniel M Junius, Edwin Rock, John L Magnani, Patricia S Andrews and Scott D Sandell.
View institutional ownership trends
.

How do I buy shares of GlycoMimetics?

Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GlycoMimetics' stock price today?

One share of GLYC stock can currently be purchased for approximately $3.09.

How much money does GlycoMimetics make?

GlycoMimetics (NASDAQ:GLYC) has a market capitalization of $161.99 million and generates $92,625.00 in revenue each year. The biotechnology company earns $-63,430,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis.

How can I contact GlycoMimetics?

GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The official website for the company is www.glycomimetics.com. The biotechnology company can be reached via phone at (240) 243-1201, via email at sannes@annesassociates.com, or via fax at 301-738-2137.

This page (NASDAQ:GLYC) was last updated on 2/5/2023 by MarketBeat.com Staff